書誌事項
- タイトル別名
-
- Concurrent Chemoradiotherapy with Docetaxel for T2N0 Laryngeal Carcinoma
- コウトウ ガン T2N0 ショウレイ ニ タイスル カガク ホウシャセン チリョウ ノ ケントウ
この論文をさがす
抄録
<p>A combination of docetaxel (DOC) therapy and radiotherapy was used to treat patients with T2N0 laryngeal carcinoma. Thirty-two patients with T2N0 laryngeal cancer received concurrent chemoradiotherapy (64.6–74 Gy) with weekly DOC (10 mg/m2). All the patients were male, and their average age was 66.3 years. All the patients achieved a complete response (CR). The overall survival rate, as determined using the Kaplan-Meier method, was 92.0%, and the disease-free survival rate was 92.2%. The local control rates were 88.0% for the glottis and 28.6% for the supraglottis and subglottis. Grade 3 or higher toxicities were seen in 4 patients. In conclusion, concurrent chemoradiotherapy with DOC is a feasible and effective treatment for glottic squamous cell carcinoma.</p>
収録刊行物
-
- 耳鼻咽喉科臨床 補冊
-
耳鼻咽喉科臨床 補冊 149 (0), 198-202, 2017
耳鼻咽喉科臨床学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001204328819840
-
- NII論文ID
- 130005529831
-
- NII書誌ID
- AN10020883
-
- ISSN
- 21851557
- 09121870
-
- NDL書誌ID
- 028140187
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可